Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1
A Systematic Review and Meta-analysis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 4, 2021
- Accepted in final form December 27, 2021
- First Published January 11, 2022.
Article Versions
- Previous version (January 11, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Jisun Hwang, MD,
- Hee Mang Yoon, MD, PhD*,
- Beom Hee Lee, MD, PhD*,
- Pyeong Hwa Kim, MD and
- Kyung Won Kim, MD, PhD
- Jisun Hwang, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hee Mang Yoon, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Beom Hee Lee, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pyeong Hwa Kim, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kyung Won Kim, MD, PhD
Safety review committee for a clinical trial of Vaxcell-Bio Therapeutics.
NONE
NONE
Cancer Imaging, Section Editor, 1 year
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Radiology (J.H.), Dongtan Sacred Heart Hospital, Hallym University Medical Center, Gyeonggi-do; and Department of Radiology and Research Institute of Radiology (H.M.Y., P.H.K., K.W.K.) and Department of Pediatrics (B.H.L.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Correspondence
Dr. Yoon espoirhm{at}gmail.com
Article usage
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.